Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available i...
Find MoreCytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufactur...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.